ObjectiveTo determine whether neurophysiological mechanisms indicating cortical excitability, longâterm potentiation (LTP)âlike plasticity, GABAergic and glutamatergic function are altered in patients with antiâNâmethylâdâaspartate receptor (NMDAR) encephalitis and whether they can be helpful as markers of diagnostic assessment, disease progression, and potentially therapy response.MethodsNeurophysiological characterizations of patients with NMDAR encephalitis (n = 34, mean age: 28 ± 11 years; 30 females) and age/genderâmatched healthy controls (n = 27, 28.5 ± 10 years; 25 females) were performed using transcranial magnetic stimulationâderived protocols including resting motor threshold, recruitment curve, intracortical facilitation, short intracortical inhibition, and cortical silent period. Paired associative stimulation (PAS) was applied to assess LTPâlike mechanisms which are mediated through NMDAR. Moreover, resting state functional connectivity was determined using functional magnetic resonance imaging.Results
PASâinduced plasticity differed significantly between groups (P = 0.0056). Cortical excitability, as assessed via motorâevoked potentials after PAS, decreased in patients, whereas it increased in controls indicating malfunctioning of NMDAR in encephalitis patients. Lower PASâinduced plasticity significantly correlated with the modified Rankin Scale (mRS) (r = â0.41; P = 0.0031) and was correlated with lower functional connectivity within the motor network in NMDAR encephalitis patients (P < 0.001, uncorrected). Other neurophysiological parameters were not significantly different between groups. Followâup assessments were available in six patients and demonstrated parallel improvement of PASâinduced plasticity and mRS.InterpretationAssessment of PASâinduced plasticity may help to determine NMDAR dysfunction and disease severity in NMDAR encephalitis, and might even aid as a sensitive, noninvasive, and wellâtolerated âelectrophysiological biomarkerâ to monitor therapy response in the future.Clinical Trial RegistrationClinicalTrials.gov: Identifier: NCT01865578